Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials-Reference-Cited by-同舟云学术

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Published:2014-03-07 Issue:5 Volume:13 Page:1117-1129
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Fritsch Christine,Huang Alan,Chatenay-Rivauday Christian,Schnell Christian,Reddy Anupama,Liu Manway,Kauffmann Audrey,Guthy Daniel,Erdmann Dirk,De Pover Alain,Furet Pascal,Gao Hui,Ferretti Stephane,Wang Youzhen,Trappe Joerg,Brachmann Saskia M.,Maira Sauveur-Michel,Wilson Christopher,Boehm Markus,Garcia-Echeverria Carlos,Chene Patrick,Wiesmann Marion,Cozens Robert,Lehar Joseph,Schlegel Robert,Caravatti Giorgio,Hofmann Francesco,Sellers William R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 394 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

2. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

3. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

4. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

5. Mechanistic modeling of cell viability assays within silicolineage tracing;2024-08-26